- Integrative Genetics Conference, all presentationsOriginal Date: September 23-24, 2017This discounted package includes all of the individual presentations from the conference.12.0 CEUs (including 3.75 pharmacy, and 8.25 general) approved by OBNM
Epigenetics And An Overview Of The Human GenomePresenter: Chris Meletis, NDOriginal Date: September 23, 2017This presentation provides an overview of human genetics and how the intricacies of the human genome are amazing dynamic with delicate intricacies that allow us to adapt to our changing environment; yet also put us at great peril due to epigenetic factors both within our control and external factors that trend towards disruption of homeostasis.The Clinical impact of stress, pharmaceuticals, environmental pollutants, sleep, etc is also discussed.1.0 CEUs (including 0.25 pharmacy & 0.75 general)approved by OBNM- Genetic Testing and Test InterpretationPresenter: Lauren Few, PhDOriginal Date: September 23, 2017Pharmacogenetics integrates the study of genomics and pharmacology to understand differential response to medications and clinical interventions. Psychiatric pharmacogenetics applies this study to mental health. This presentation focuses on several genetic variants that have been shown to moderate treatment response with a particular emphasis on how these variations may direct clinicians to certain integrative therapies (e.g., exercise, Omega-3 fatty acids, L-methylfolate, etc.). Both pharmacodynamic and pharmacokinetic gene variants are discussed.2.0 pharmacy CEUs approved by OBNM
- Dirty Genes: Born Dirty or Got Dirty?Presenter: Ben Lynch, NDOriginal Date: September 23, 2017Genomic medicine is putting eggs into the SNP basket. But what if your patient is not born with SNPs? You swore they had MTHFR, COMT and others yet SNPs are not present. Other patients seem to be absolutely healthy yet they are born with a myriad of significant SNPs. What’s going on?! Learn how to incorporate gene function in your practice so you are prepared for either situation.1.5 general CEUs approved by OBNM
- Do Genetics Really Matter? A Case StudyPresenter: Ben Lynch, NDOriginal Date: September 23, 2017A middle-aged woman is struggling with panic attacks for most her life. She wonders if genetics is something she should look into or not. She gets her genetic report and has no clue what it means. Dr. Lynch works through a case study incorporating history, SNPs and pathways to discover what is triggering her panic attacks - and why...1.5 general CEUs approved by OBNM
- Catch Up And Move ForwardPresenter: Paul Anderson, NMDOriginal Date: September 24, 2017The purpose of this presentation is to allow the attendee a chance to “catch up” after a full day of genomic presentations and get an introduction to the day’s material. Dr. Anderson presents several case studies on patients he has managed. A “1-2-3” approach will be presented which outlines how practitioners can “troubleshoot” the treatment issues that happen when either the patient “self-treats” or has an unusual reaction to a nutrigenomic therapy.Pharmaceuticals discussed in case presentations will include Deplin, Metanx, Buproprion, and Diphenhydramine.1.5 CEUs (including 0.5 pharmacy & 1.0 general) approved by OBNM
Detoxification, “Detoxigenomics” And How to Use Genomics To Augment DetoxificationPresenter: Paul Anderson, NMDOriginal Date: September 24, 2017How do the three phases of detoxification work? How do pharmaceuticals affect them? A common area of misunderstood reactivity is sulfite oxidation, which often is mistaken for a Type-1 histamine reaction. This session is designed to give clarity to the signs of these reactions as well as prevention and treatment strategies. Phase-2 is dominated by Glutathione and Glycine but also these “back-up” hydroxyl reduction in Phase-1. How do pharmaceuticals affect these supports, how clinically can we assess and support them and what does it look like clinically when they are overwhelmed? Additional case studies are discussed.Pharmaceuticals discussed in case presentations will include Mucomyst, Succimer, acetaminophen, codeine, ciclosporin and diazepam.1.5 CEUs (including 0.5 pharmacy & 1.0 general) approved by OBNM- Neuro-Psychiatric Genomic Influences – When It Isn’t all In Their HeadPresenter: Paul Anderson, NMDOriginal Date: September 24, 2017What are the basics of “cause” in the areas of agitation and sleep problems. What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous GABA, Glycine and other calming neurotransmitters benefit and refine your therapies?What are the basics of “cause” in the areas of depression? What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous serotonin, dopamine and norepinephrine neurotransmitters benefit and refine your therapies?How does the brain become inflamed and how does that affect neuropsychiatric status? What genomic and nutrigenomic factors can alter this status and restore the brain to a non-inflamed state?Dr. Anderson discusses case studies that he has worked through in neuro-psychiatric conditions and how they played out. The goal of these cases is to illustrate how genomic assessment and nutrigenomics cross over pharmacology and how they can be implemented clinically.1.5 CEUs (including 0.5 pharmacy & 1.0 general) approved by OBNM
- Wrap Up And Making Sense Of It AllPresenter: Paul Anderson, NMDOriginal Date: September 24, 2017Dr. Anderson reviews and synthesizes all of the content from the prior three presentations. Guidelines are presented for practitioners who are just starting out with pharmacogenomics and other forms of genetic testing. Practitioners are given advice on how to get started, how to avoid feeling overwhelmed, and what their top priorities should be for integrating these practices in their clinic.1.5 general CEUs approved by OBNM
